Sulfamethoxazole is a synthetic antibacterial drug,which is used in combination with trimethoprim (Bactrim, Septra) for the treatment or prevention of infections that are proven or strongly suspected to be caused by bacteria. Sulfamethoxazole acts by inhibiting folic acid synthesis via enzyme called dihydropteroate synthase.

Sulfasymazine is a sulfanilamide derivative patented by American Cyanamid Co. as antibacterial agents for Staphylococcus and Streptococcus infections. In preclinical models, Sulfasymazine shows activity on a dosage basis ranged from 2- to 10-fold that of sulfisoxazole, and from 1/3 to equal on a blood-level basis, but was not as potent as sulfadiazine.

Glyprothiazol (VK 57 or RP 2254) is a sulfonamide derivative. This compound lowers blood glucose levels by increasing the release of insulin from the pancreas. It stimulates insulin secretion through a direct action on pancreatic islets. Glyprothiazol was the first of oral hypoglycemic sulfonamides used in the treatment of type 2 diabetes mellitus.

Sulfatroxazole is a sulfamide derivative patented by Swiss multinational healthcare company F. Hoffmann-La Roche & Co., A.-G. as an antibacterial agent and bacteriostatic antibiotic. Sulfatroxazole competitively inhibits dihydropteroate synthase preventing the formation of dihydropteroic acid, a precursor of folic acid which is required for bacterial growth. Sulfatroxazole is a component present in various veterinary drugs.

Glybuthiazole is a sulfonamide derivative with antihyperglycemic activity, which possesses anti-diabetic properties. It is able to lower blood glucose levels by increasing the release of insulin from pancreatic beta cells.

Delfantrine is an analgesic, antiinflammatory agent, developed by Ciba.